{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:40:45Z","timestamp":1753890045257,"version":"3.41.2"},"reference-count":22,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,20]]},"DOI":"10.31744\/einstein_journal\/2024gs0413","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T17:46:37Z","timestamp":1716313597000},"source":"Crossref","is-referenced-by-count":0,"title":["Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population"],"prefix":"10.31744","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-6482","authenticated-orcid":false,"given":"Ana Clara Maia","family":"Palhano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5931-5730","authenticated-orcid":false,"given":"Ninna Medeiros","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas Sousa Vecchio dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8412-4290","authenticated-orcid":false,"given":"Rita","family":"Narikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8899-7189","authenticated-orcid":false,"given":"Andr\u00e9","family":"Ballalai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-9330","authenticated-orcid":false,"given":"Dimitri Luz Felipe da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"key":"key20240521134631_B1","first-page":"86","volume-title":"Manual de dermatologia cl\u00ednica de Sampaio e Rivitti","author":"Rivitti","year":"2014","unstructured":"1. Rivitti E. Manual de dermatologia cl\u00ednica de Sampaio e Rivitti. S\u00e3o Paulo: Artes M\u00e9dicas; 2014. p. 86-92."},{"issue":"5","key":"key20240521134631_B2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000450826","article-title":"Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis","volume":"232","author":"Gonzalez","year":"2016","unstructured":"2. Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A. Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis. Dermatology. 2016;232(5):541-9. Review.","journal-title":"Dermatology"},{"issue":"4","key":"key20240521134631_B3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jjcc.2018.10.008","article-title":"Risk of myocardial infarction in patients with psoriasis: A cross-sectional patient-population study in a Japanese hospital","volume":"73","author":"Shiba","year":"2019","unstructured":"3. Shiba M, Kato T, Izumi T, Miyamoto S, Nakane E, Haruna T, et al. Risk of myocardial infarction in patients with psoriasis: A cross-sectional patient-population study in a Japanese hospital. J Cardiol. 2019;73(4):276-9.","journal-title":"J Cardiol"},{"issue":"3","key":"key20240521134631_B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.12788\/j.sder.2018.048","article-title":"Targeted therapies for pediatric psoriasis","volume":"37","author":"Schwartz","year":"2018","unstructured":"4. Schwartz G, Paller AS. Targeted therapies for pediatric psoriasis. Semin Cutan Med Surg. 2018;37(3):167-72. Review.","journal-title":"Semin Cutan Med Surg"},{"issue":"8","key":"key20240521134631_B5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/09546634.2018.1466023","article-title":"Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT)","volume":"29","author":"Romiti","year":"2018","unstructured":"5. Romiti R, Fabr\u00edcio LH, Souza CD, Galv\u00e3o LO, de Castro CC, Terena AC, et al. Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). J Dermatolog Treat. 2018;29(8):775-85.","journal-title":"J Dermatolog Treat"},{"key":"key20240521134631_B6","author":"Brasil","year":"2018","unstructured":"6. Brasil. Minist\u00e9rio da sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos. Ixequizumabe para tratamento de pacientes adultos com psor\u00edase moderada a grave, que tenham apresentado falha terap\u00eautica, contraindica\u00e7\u00e3o ou intoler\u00e2ncia ao adalimumabe [Relat\u00f3rio de recomenda\u00e7\u00e3o n o 385]. Bras\u00edlia (DF): Minist\u00e9rio da sa\u00fade; 2018 [citado 2022 Out 10]. Dispon\u00edvel em: http:\/\/antigo-conitec.saude.gov.br\/images\/Consultas\/Relatorios\/ 2020\/Relatorio_Ixequizumabe_psoriase_SEC_535_27_2020_final.pdf","journal-title":"Ixequizumabe para tratamento de pacientes adultos com psor\u00edase moderada a grave, que tenham apresentado falha terap\u00eautica, contraindica\u00e7\u00e3o ou intoler\u00e2ncia ao adalimumabe [Relat\u00f3rio de recomenda\u00e7\u00e3o n o 385]"},{"key":"key20240521134631_B7","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)","year":"2021","unstructured":"7. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Medicamentos. Secuquinumabe [bula]. Novartis Bioci\u00eancias S.A. Respons\u00e1vel T\u00e9cnico Flavia Regina Pegorer. Bras\u00edlia (DF): ANVISA; 2021 [citado 2022 Out 10]. Dispon\u00edvel em: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/25351101731201491\/?substancia=25708","journal-title":"Medicamentos. Secuquinumabe [bula]. Novartis Bioci\u00eancias S.A. Respons\u00e1vel T\u00e9cnico Flavia Regina Pegorer"},{"issue":"6","key":"key20240521134631_B8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: a review in moderate to severe pediatric plaque psoriasis","volume":"23","author":"Blair","year":"2021","unstructured":"8. Blair HA. Secukinumab: a review in moderate to severe pediatric plaque psoriasis. Paediatr Drugs. 2021;23(6):601-8. Erratum in: Paediatr Drugs. 2022;24(1):91. Review.","journal-title":"Paediatr Drugs"},{"key":"key20240521134631_B9","author":"Brasil","year":"2021","unstructured":"9. Brasil. Minist\u00e9rio da Sa\u00fade. Contratos do Departamento de Log\u00edstica em Sa\u00fade (DLOG). Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2021 [citado 2022 Out 10]. Dispon\u00edvel em: https:\/\/www.gov.br\/saude\/pt-br\/acesso-a-informacao\/licitacoes-e-contratos\/contratos-dlog","journal-title":"Contratos do Departamento de Log\u00edstica em Sa\u00fade (DLOG)"},{"issue":"2","key":"key20240521134631_B10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/abd1806-4841.2019940211","article-title":"Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology","volume":"94","author":"Arnone","year":"2019","unstructured":"10. Arnone M, Takahashi MD, Carvalho AV, Bernardo WM, Bressan AL, Ramos AM, et al. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):76-107.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"key20240521134631_B11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2014.05.001","article-title":"Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting","volume":"71","author":"Takeshita","year":"2014","unstructured":"11. Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71(4):633-41.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"key20240521134631_B12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","unstructured":"12. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Sch\u00e4fer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-6.","journal-title":"Br J Dermatol"},{"issue":"6","key":"key20240521134631_B13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study","volume":"62","author":"Tollefson","year":"2010","unstructured":"13. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979-87.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"key20240521134631_B14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00431-011-1587-2","article-title":"Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases","volume":"171","author":"Varni","year":"2012","unstructured":"14. Varni JW, Globe DR, Gandra SR, Harrison DJ, Hooper M, Baumgartner S. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485-92.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"key20240521134631_B15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1590\/abd1806-4841.20164228","article-title":"Use of clobetasol in lacquer for plaque psoriasis treatment","volume":"91","author":"da Silva","year":"2016","unstructured":"15. da Silva SA, Magalh\u00e3es RF, Torres RA, de Oliveira RD, Velho PE. Use of clobetasol in lacquer for plaque psoriasis treatment. An Bras Dermatol. 2016;91(1):113-5.","journal-title":"An Bras Dermatol"},{"issue":"5","key":"key20240521134631_B16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/09546634.2016.1254331","article-title":"Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review","volume":"28","author":"Svendsen","year":"2017","unstructured":"16. Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2017;28(5):374-83. Review.","journal-title":"J Dermatolog Treat"},{"key":"key20240521134631_B17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/CCID.S81160","article-title":"Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab","volume":"9","author":"Malakouti","year":"2016","unstructured":"17. Malakouti M, Jacob SE, Anderson NJ. Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab. Clin Cosmet Investig Dermatol. 2016;9:347-55. Review.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key20240521134631_B18","author":"Sociedade Brasileira de Dermatologia (SBD)","year":"2020","unstructured":"18. Sociedade Brasileira de Dermatologia (SBD). Consenso Brasileiro de Psor\u00edase 2020: algoritmo de tratamento da Sociedade Brasileira de Dermatologia. 3a ed. Rio de Janeiro: SBD; 2020. 138p.","journal-title":"Consenso Brasileiro de Psor\u00edase 2020: algoritmo de tratamento da Sociedade Brasileira de Dermatologia"},{"issue":"4","key":"key20240521134631_B19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","unstructured":"19. Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603.","journal-title":"J Am Acad Dermatol"},{"key":"key20240521134631_B20","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)","year":"2021","unstructured":"20. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Medicamentos. Ustequinumabe [bula]. Janssen Cilag Farmac\u00eautica Ltda. Respons\u00e1vel t\u00e9cnico: Erika Diago Rufino. Bras\u00edlia (DF): ANVISA; 2021 [citado 2022 Out 10]. Dispon\u00edvel em: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/25351630200200806\/?substancia=25220","journal-title":"Medicamentos. Ustequinumabe"},{"key":"key20240521134631_B21","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)","year":"2021","unstructured":"21. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Lista de pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo, para compras p\u00fablicas. Bras\u00edlia (DF): ANVISA; 2021 [citado 2022 Out 10]. Dispon\u00edvel em: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed\/precos","journal-title":"Lista de pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo, para compras p\u00fablicas"},{"key":"key20240521134631_B22","author":"Brasil","year":"2012","unstructured":"22. Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos Departamento de Ci\u00eancia e Tecnologia. Diretrizes metodol\u00f3gicas: an\u00e1lise de impacto or\u00e7ament\u00e1rio: manual para o Sistema de Sa\u00fade do Brasil. [S\u00e9rie A: Normas e Manuais T\u00e9cnicos]. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2012 [citado 2022 Out 10]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/diretrizes_metodologicas_analise_impacto.pdf","journal-title":"Diretrizes metodol\u00f3gicas: an\u00e1lise de impacto or\u00e7ament\u00e1rio: manual para o Sistema de Sa\u00fade do Brasil"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T17:46:52Z","timestamp":1716313612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/unmet-need-for-and-impact-of-adopting-immunobiological-drugs-for-moderate-to-severe-plaque-psoriasis-in-a-pediatric-population\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"alternative-id":["10.31744\/einstein_journal\/2024GS0413"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2024gs0413","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"type":"print","value":"1679-4508"},{"type":"electronic","value":"2317-6385"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"eGS0413"}}